170 related articles for article (PubMed ID: 36970726)
21. The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.
Lawson M; Cureton N; Ros S; Cheraghchi-Bashi A; Urosevic J; D'Arcy S; Delpuech O; DuPont M; Fisher DI; Gangl ET; Lewis H; Trueman D; Wali N; Williamson SC; Moss J; Montaudon E; Derrien H; Marangoni E; Miragaia RJ; Gagrica S; Morentin-Gutierrez P; Moss TA; Maglennon G; Sutton D; Polanski R; Rosen A; Cairns J; Zhang P; Sánchez-Guixé M; Serra V; Critchlow SE; Scott JS; Lindemann JPO; Barry ST; Klinowska T; Morrow CJ; Carnevalli LS
Cancer Res; 2023 Dec; 83(23):3989-4004. PubMed ID: 37725704
[TBL] [Abstract][Full Text] [Related]
22. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
[TBL] [Abstract][Full Text] [Related]
23. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
24. Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer.
Kaklamani VG; Richardson AL; Arteaga CL
Oncologist; 2019 Mar; 24(3):305-312. PubMed ID: 30651399
[TBL] [Abstract][Full Text] [Related]
25. Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer.
Gonzalez ME; DuPrie ML; Krueger H; Merajver SD; Ventura AC; Toy KA; Kleer CG
Cancer Res; 2011 Mar; 71(6):2360-70. PubMed ID: 21406404
[TBL] [Abstract][Full Text] [Related]
26. Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
Salvati A; Melone V; Sellitto A; Rizzo F; Tarallo R; Nyman TA; Giurato G; Nassa G; Weisz A
Breast Cancer Res; 2022 Jul; 24(1):52. PubMed ID: 35850772
[TBL] [Abstract][Full Text] [Related]
27. Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors.
Clement E; Inuzuka H; Nihira NT; Wei W; Toker A
Sci Signal; 2018 Mar; 11(521):. PubMed ID: 29535262
[TBL] [Abstract][Full Text] [Related]
28. Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER
Hosford SR; Dillon LM; Bouley SJ; Rosati R; Yang W; Chen VS; Demidenko E; Morra RP; Miller TW
Clin Cancer Res; 2017 Jun; 23(11):2795-2805. PubMed ID: 27903677
[No Abstract] [Full Text] [Related]
29. Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway.
Brufsky AM
Breast J; 2014; 20(4):347-57. PubMed ID: 24861776
[TBL] [Abstract][Full Text] [Related]
30. Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression.
Polo ML; Riggio M; May M; Rodríguez MJ; Perrone MC; Stallings-Mann M; Kaen D; Frost M; Goetz M; Boughey J; Lanari C; Radisky D; Novaro V
Oncotarget; 2015 Sep; 6(26):22081-97. PubMed ID: 26098779
[TBL] [Abstract][Full Text] [Related]
31. Synergistic actions of Alpelisib and Melatonin in breast cancer cell lines with PIK3CA gene mutation.
de Godoy BLV; Moschetta-Pinheiro MG; Chuffa LGA; Pondé NF; Reiter RJ; Colombo J; Zuccari DAPC
Life Sci; 2023 Jul; 324():121708. PubMed ID: 37086897
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
Yi YW; Kang HJ; Kim HJ; Hwang JS; Wang A; Bae I
Mol Carcinog; 2013 Sep; 52(9):667-75. PubMed ID: 22488590
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of PI3K inhibitors in advanced breast cancer.
Verret B; Cortes J; Bachelot T; Andre F; Arnedos M
Ann Oncol; 2019 Dec; 30(Suppl_10):x12-x20. PubMed ID: 31859349
[TBL] [Abstract][Full Text] [Related]
34. Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.
Leroy C; Ramos P; Cornille K; Bonenfant D; Fritsch C; Voshol H; Bentires-Alj M
Breast Cancer Res; 2016 Apr; 18(1):41. PubMed ID: 27048245
[TBL] [Abstract][Full Text] [Related]
35. Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression.
Bowers LW; Cavazos DA; Maximo IX; Brenner AJ; Hursting SD; deGraffenried LA
Breast Cancer Res; 2013; 15(4):R59. PubMed ID: 23880059
[TBL] [Abstract][Full Text] [Related]
36. KDM6B Counteracts EZH2-Mediated Suppression of
Wang W; Lim KG; Feng M; Bao Y; Lee PL; Cai Y; Chen Y; Zhang H; Marzese D; Hoon DSB; Yu Q
Mol Cancer Ther; 2018 Sep; 17(9):1973-1983. PubMed ID: 29925528
[TBL] [Abstract][Full Text] [Related]
37. Automethylation activities within the mixed lineage leukemia-1 (MLL1) core complex reveal evidence supporting a "two-active site" model for multiple histone H3 lysine 4 methylation.
Patel A; Vought VE; Swatkoski S; Viggiano S; Howard B; Dharmarajan V; Monteith KE; Kupakuwana G; Namitz KE; Shinsky SA; Cotter RJ; Cosgrove MS
J Biol Chem; 2014 Jan; 289(2):868-84. PubMed ID: 24235145
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
Araki K; Miyoshi Y
Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
[TBL] [Abstract][Full Text] [Related]
39. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
[TBL] [Abstract][Full Text] [Related]
40. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
Ippen FM; Grosch JK; Subramanian M; Kuter BM; Liederer BM; Plise EG; Mora JL; Nayyar N; Schmidt SP; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
Neuro Oncol; 2019 Nov; 21(11):1401-1411. PubMed ID: 31173106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]